MEI Pharma, Inc. 是一家從事藥品化合物開發的製藥公司。公司總部位於美國加州聖地牙哥,目前聘有28名全職員工。該公司在2003年12月18日上市。該公司的資金計畫以萊特幣為基礎。公司已終止voruciclib的臨床開發,但與其候選藥物資產相關的某些非臨床活動仍在繼續進行。作為戰略選擇評估的一部分,公司可能會考慮現有項目的外部授權機會以及合併與收購機會。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for LITS. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: LITS is a Sell candidate.
LITS stock price ended at $1.12 on 星期五, after rising 8.74%
On the latest trading day Feb 13, 2026, the stock price of LITS rose by 8.74%, climbing from $1.06 to $1.12. During the session, the stock saw a volatility of 9.43%, with prices oscillating between a daily low of $1.06 and a high of $1.16. Notably, trading volume dropped by 128.9K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 403.5K shares were traded, equating to a market value of approximately $41.2M.